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Abstract 
The principal mechanism by which bronchodilator ȕ-adrenoceptor agonists act is to 
relax airways smooth muscle although they may also be anti-inflammatory. However, 
the extent of anti-inflammatory activity and the cell types affected by these agonists 
are uncertain.  The purpose of this study was to evaluate whether ȕ-adrenoceptor 
agonists prevent pro-inflammatory cytokine generation from activated human lung 
macrophages.  Macrophages were isolated and purified from human lung. The cells 
were pre-treated with both short-acting (isoprenaline, salbutamol, terbutaline) and 
long-acting (formoterol, salmeterol, indacaterol) ȕ-agonists before activation with 
lipopolysaccharide (LPS) to induce cytokine 71)Į,/-6, IL-8 and IL-10) 
generation. The experiments showed that short-acting ȕ-agonists were poor inhibitors 
of cytokine generation.  Of the long-acting ȕ-agonists studied, formoterol was also a 
weak inhibitor of cytokine generation whereas only indacaterol and salmeterol 
showed moderate inhibitory activity. Further experiments using the ȕ2-adrenoceptor 
antagonist ICI-118,551 suggested that the effects of indacaterol were likely to be 
mediated by ȕ2-adrenoceptors whereas those of salmeterol were not. These findings 
were corroborated by functional desensitization studies in which the inhibitory effects 
of indacaterol appeared to be receptor-mediated whereas those of salmeterol were not.  
Taken together, the data indicate that the anti-inflammatory effects of ȕ-adrenoceptor 
agonists on human lung macrophages are modest.     
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1. Introduction 
ȕ-adrenoceptor agonists are used as bronchodilators in the treatment of respiratory 
diseases (Waldeck, 2002; Cazzola et al., 2012).  In addition to bronchodilation, ȕ-
agonists may also possess anti-inflammatory activity (Barnes, 2006; Theron et al., 
2013).   Both in vitro and in vivo studies suggest that ȕ-agonists may dampen 
inflammation although there are inconsistencies (Schild, 1937; 2¶&RQQRUHWDO
Maris et al., 2004, Maris et al., 2005; Bosmann et al., 2012; Wex et al., 2015).  It is 
noteworthy that in many of these studies animal models or cell lines have been 
employed.  How representative these models are of human systems is open to 
interpretation. 
 The human lung macrophage plays an important role in innate and adaptive 
immune responses in the lung (Gordon, 2007).  However, increased numbers of 
macrophages and excessive activation of these cells have been associated with 
respiratory diseases especially COPD (Peters-Golden, 2004; Barnes, 2008; Yang et 
al., 2012).  Attenuating excessive macrophage activation would be expected to be 
benefical in the treatment of respiratory diseases.  Studies investigating the effects of 
ȕ-agonists on monocytes, monocyte-derived macrophages (MDM) and macrophage-
like cell lines suggest that these drugs may modulate a number of macrophage 
functions including the prevention of pro-inflammatory cytokine generation 
(Yoshimura et al., 1997; Izeboud et al., 1999; Donnelly et al., 2010; Shirato et al, 
2013).  By contrast, other studies show limited effects of ȕ-agonists in these systems 
(Linden, 1992; Zetturlund et al., 1998; Ezeamuzie and Shihab, 2010).  As a 
consequence, no consistent evidence has emerged to determine whether ȕ-agonists 
effectively attenuate the pro-inflammatory activity of macrophages.  This is 
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particularly true for human alveolar macrophages in which very few studies have been 
performed to investigate the effects of ȕ-agonists on these cells.        
The aim of the present study, therefore, was to determine whether ȕ-agonists 
are effective inhibitors of pro-inflammatory cytokine release from macrophages 
isolated from human lung.  To this end, a range of both short- and long-acting ȕ-
agonists were evaluated. 
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2. Materials and methods 
2.1 Buffers   
Phosphate buffered saline (PBS) contained (mM): NaCl 137; Na2HPO4.12H2O 8; KCl 
2.7; KH2PO4 1.5.  PIPES buffer contained (mM): PIPES (22), NaCl (110), KCl (5) 
and the pH was titrated to 7.4 with NaOH.  
 
2.2 Preparation of compounds 
Stock solutions (10 mM) of salmeterol, formoterol and indacaterol were prepared in 
dimethyl sulphoxide and stored at 4 °C.  Salbutamol, terbutaline and ICI-118,551 were 
prepared as stock solutions (10 mM) dissolved in distilled water and stored at 4 °C.  
Stock solutions (10 mM) of (-)-isoprenaline bitartrate were prepared in 0.05% sodium 
metabisulphite (dissolved in 0.9% saline) and stored at 4 °C.  LPS from E. coli 
serotype R515 (Re) was provided as a 1 mg/ml stock solution and stored at 4 °C.  
Poly(I:C)-LMW stock solution (10 mg/ml) was prepared in distilled water and stored 
at -20 °C. 
 
2.3 Lung tissue 
Lung tissue was obtained from surgical resections.  Thirty-two lung preparations were 
used in this study, 21 preparations were derived from males and 11 from females.  
The age range of participants was 29 to 88 years with a median age of 68.  Informed 
written consent was obtained in order to use the lung tissue for the experiments 
described in this study.  The use of lung tissue was approved by the National Research 
(WKLFV¶Service, UK (REC reference: 15/NW/0657).  
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2.4 Macrophage isolation                                                                                                
Macrophages were isolated from lung tissue using a modification of the protocol 
described by Liu and colleagues (1984).  In brief, lung tisue was chopped extensively 
in RPMI-1640 buffer (containing L-glutamine) and the tissue filtered over ȝP
nylon mesh (Incamesh, Warrington, UK).  The filtrate (~200 ml) was centrifuged 
(300 g, 10 min, room temperature) and the pellets resuspended in ~40 ml of RPMI-
1640 supplemented with 10% heat inactivated FBS (foetal bovine serum), penicillin 
(25 U/mLVWUHSWRP\FLQȝJml), JHQWDPLFLQȝJml) and fungizone (1 ȝJPO).  
The cell suspensions were left to sediment at 4 oC for 1 h.  After sedimentation, the 
supernatant was aspirated and the sedimentation step at 4 oC was repeated. The 
sedimented material was resuspended in 30 ml PIPES buffer and centrifuged (300 g, 
10 min, room temperature).  The resulting pellet was resuspended in PIPES buffer.  
The suspension was then filtered through nylon mesh before being reconstituted in 
PIPES buffer (20 ml for every 5 g of tissue).  
The resuspended cells (20 ml) were layered over an 80% Percoll gradient (20 
ml) and centrifuged (400 g, 20 min, room temperature).  The interface was harvested 
and two washes were performed with PIPES buffer (50 ml).  After centrifugation, 
(488 g, 10 min at room temperature) the pellet was resuspended in supplemented 
RPMI-1640 (~10 ml).  The cells were then counted using a haemocytometer.  
Macrophages were seeded at 2 x 105 per well in 24-well cell culture plates in 
supplemented RPMI-1640 (1ml per well) and incubated overnight (37 oC, 5% CO2). 
Cytospins were prepared (Thermo Shandon Cytospin 3) and from these the 
purity of cell suspensions was determined by morphology.  Cytospins were stained 
with Quick-Diff and processed DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV  Cell 
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viability was assessed by erythrosin-B exclusion.  Macrophage purity was 86±2% and 
cell viability was 92±1%. 
 
2.5 Preparation of monocyte-derived macrophages (MDM)  
Human peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque 
density gradient centrifugation from whole blood obtained from healthy volunteers, 
who gave informed written consent. Approval was granted by the South Sheffield 
Research Ethics¶ Committee (REC reference: 07/Q2305/7). PBMC were seeded at 2 x 
106 cells/ml in 24 well plates in RPMI-1640 supplemented with 10% heat inactivated 
newborn calf serum. After 24 h, non-adherent cells were removed and adherent cells 
were cultured in RPMI-1640 supplemented with 10% heat inactivated FBS to give a 
final concentration of approximately 2 x 105 MDM/well at 14 days (Dockrell et al., 
2001). 
 
2.6 Macrophage activation protocol 
After overnight incubation, medium from the wells was replaced with supplemented 
RPMI-1640 buffer (1 ml) and incubated (37 oC, 5% CO2) for 2 h before the start of 
the experiment. Where agonists and antagonists were used, cells were pre-incubated 
for 30 to 60 min with these ligands before addition of stimulus for 22 h.  The cell 
culture supernatants were harvested and centrifuged (488 g, 4 min, room temperature) 
and the resulting supernatants stored at -80 oC for analysis of cytokine content.  
71)Į,/-6, IL-8 and IL-10 were analysed using commercially-available ELISA kits 
(RSG kits, eBioscience, Hatfield, UK).   
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2.7 Materials   
The following were purchased from the sources indicated: dimethyl sulphoxide, 
fungizone, indomethacin, isoprenaline, penicillin/streptomycin, Percoll, PIPES, 
salbutamol, terbutaline, (all Sigma, Poole, UK); gentamicin, heat inactivated FBS, 
heat inactivated newborn calf serum (Gibco, Paisley, UK); RPMI-1640 containing L-
glutamine (Lonza, Slough, UK); salmeterol, ICI-118,551 (Tocris Bioscience, Bristol, 
UK); Quick-Diff (Reagena, Toivala, Finland); Ficoll-Paque (GE Healthcare Life 
Sciences, Little Chalfont, UK); LPS (Enzo Life Sciences, Exeter, UK);  Poly(I:C)-
LMW (InvivoGen, CA, USA); indacaterol maleate and formoterol fumarate were a 
kind gift of Novartis (Horsham, UK). 
 
2.8 Data analysis 
Values are expressed as means ± S.E.M.  Statistical significance was performed 
utilising either ANOVA followed by post hoc testV'XQQHWW¶VRU7XNH\¶VWHVWV or 
paired and unpaired 6WXGHQW¶Vt-tests as appropriate. 
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3. Results 
3.1 Long-acting ȕ-agonists are more effective than short-acting ȕ-agonists as 
inhibitors of cytokine generation 
The effects of short-acting and long-acting ȕ-adrenoceptor agonists on LPS-induced 
cytokine generation from human lung macrophages were investigated (Fig. 1).  
Neither isoprenaline, terbutaline nor salbutamol had any significant (P>0.05) 
inhibitory effects on cytokine generation from macrophages.  By contrast, the long-
acting ȕ-agonists, indacaterol and salmeterol were effective (P<0.05) inhibitors of 
71)Į (Fig. 1A) and IL-6 (Fig. 1B), reducing cytokine generation from activated 
macrophages by ~40%. However, indacaterol and salmeterol were ineffective as 
inhibitors of IL-8 generation (Fig. 1C).  The long-acting ȕ-agonist, formoterol, was 
ineffective as an inhibitor of the stimulated release of all the cytokines investigated.  
The steroid dexamethasone was included as a positive control in these experiments.  
Dexamethasone was a highly effective inhibitor of TNFĮ, IL-6 and IL-8 generation 
reducing the stimulated release of all three cytokines by ~80%. 
 As well as studies investigating pro-inflammatory cytokine generation from 
PDFURSKDJHVWKHSRWHQWLDOHIIHFWVRIȕ-adrenoceptor agonists on the anti-
inflammatory cytokine, IL-10, were determined (Fig. 1D).  1RQHRIWKHȕ-
adrenoceptor agonists studied induced IL-10 generation when used alone (data not 
shown).  LPS activation of macrophages led to modest release of IL-10 generation.  
None of WKHȕ-adrenoceptor agonists studied, with the exception of salmeterol, had 
any effect on LPS-induced IL-10 generation whereas dexamethasone was a highly 
effective inhibitor.  
 The effects of ȕ-agonists on the generation of TNFĮ from macrophages 
induced by either LPS or the viral mimic poly(I:C) were investigated (Fig. 2).  
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Salbutamol was ineffective as an inhibitor of TNFĮ generation induced by both 
stimuli whereas salmeterol and indacaterol were effective against LPS-induced TNFĮ 
generation but not that driven by poly(I:C).  Dexamethasone was an effective 
inhibitor of TNFĮ generation driven by either stimulus. 
 The possibility that the relative ineffectiveness of short-acting ȕ-agonists to 
inhibit cytokine generation might be related to the strength of the stimulus was 
investigated (Fig. 3).  The effects of salbutamol on TNFĮ generation following 
activation of macrophages with a range of concentrations of LPS (0.1, 1 and 10 
ng/ml) were studied.  Salbutamol inhibited TNFĮ generation to a modest (~30%) but 
statistically significant (P<0.05) extent when macrophages were activated with lower 
(< 10 ng/ml) concentrations of LPS. 
 Macrophages have been shown to release prostaglandin E2 (PGE2) following 
activation with LPS and the addition of exogenous PGE2 is known to inhibit 
macrophage responses (Rowe et al., 1997; Ratcliffe et al., 2007; Buenestado et al., 
2012).  This LPS-induced PGE2 may act in a paracrine fashion to inhibit macrophage 
responses and this might interfere with the inhibitory activity of ȕ-agonists.  To 
establish whether this might be the case, the inhibitory activity of salbutamol was 
investigated in the absence and presence of the cyclooxygenase inhibitor 
indomethacin (Fig. 4).  Preliminary studies of ours showed that indomethacin (1 µM) 
completely blocked the generation of PGE2 from macrophages activated with LPS 
(data not shown).  The extent to which salbutamol inhibited LPS-induced TNFĮ 
generation was very similar whether indomethacin was present or not. 
 
ȕ-adrenoceptor agonists are more effective in MDM than in lung macrophages 
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Previous studies have demonstUDWHGWKDWȕ-adrenoceptor agonists are effective 
inhibitors of cytokine generation from MDM (Donnelly et al., 2010).  The effects of 
both short-acting and long-DFWLQJȕ-agonists on cytokine generation from LPS 
activated MDM were investigated (Fig. 5). In contrast to the situation seen with 
human lung macrophages, the data show that both short-acting and long-DFWLQJȕ-
DJRQLVWVZHUHHIIHFWLYHLQKLELWRUVRI71)Įgeneration from MDM. 
 
3.3 The effects of indacaterol, but not salmeterol, are ȕ-adrenoceptor-mediated 
The effects of the ȕ2-adrenoceptor antagonist, ICI-118,551, on the inhibitory effects of 
indacaterol and salmeterol were evaluated (Fig. 6).  Pretreatment of macrophages with 
ICI-118,551 partly reversed the inhibitory effects of indacaterol against LPS-induced 
TNFĮ generation.  By contrast, the inhibitory effects of salmeterol were not reversed 
by ICI-118,551. 
To investigate further the mechanism by which indacaterol and salmeterol 
inhibit cytokine generation from macrophages, functional desensitization experiments 
were performed.  Overnight incubation of macrophages with indacaterol abolished the 
subsequent ability of indacaterol to inhibit LPS-induced TNFĮ generation (Fig. 7A).  
By contrast, overnight treatment with salmeterol did not affect the inhibitory activity 
of salmeterol (Fig. 7B).   
Cross-desensitization experiments were also performed.  Long-term treatment 
with indacaterol had no effect on the subsequent salmeterol inhibition of TNFĮ 
generation (data not shown).  Interpretation of the converse experiment where 
macrophages were treated with salmeterol overnight and then the inhibitory effects of 
indacaterol investigated were difficult to interpret because of a persisting residual 
inhibitory effect of salmeterol (data not shown).   
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4. Discussion 
In the present study we have investigated the effects of short-acting and long-acting ȕ-
agonists on pro-inflammatory cytokine release from human lung macrophages.  Our 
data demonstrate that long-acting ȕ-agonists display superior anti-inflammatory 
activity than short-acting ȕ-agonists although overall the inhibitory effects of this 
class of drugs are modest.      
 The effects of a number of short-acting ȕ-agonists on LPS-induced cytokine 
generation from macrophages were investigated.  Neither salbutamol nor terbutaline 
was particularly effective as an inhibitor of cytokine generation from macrophages.  
As salbutamol and terbutaline are generally recognised as SDUWLDODJRQLVWVDWWKHȕ2-
adrenoceptor (Cazzola et al., 2012), the effects of the full agonist, isoprenaline, were 
also studied.  Isoprenaline was essentially ineffective as an inhibitor of cytokine 
generation.  However, it should be noted that isoprenaline as well as being short-
acting is known to be susceptible to metabolism (Cazzola et al., 2012).  These factors 
may have limited the potential inhibitory effects of isoprenaline.  
 The possibility that aspects of the experimental system might have influenced 
the inhibitory effects of short-acting ȕ-agonists were considered.  For example, the 
strength of the activating stimulus, LPS, was evaluated and when sub-maximal 
concentrations of LPS were used to activate macrophages, salbutamol was moderately 
more effective as an inhibitor.  In further studies we wondered whether the 
endogenous production of PGE2 might mask responses to ȕ-agonists.  It is known that 
macrophages produce PGE2 in response to LPS and PGE2 is inhibitory in 
macrophages (Rowe et al., 1997; Ratcliffe et al., 2007; Buenestado et al., 2012; Birrel 
et al., 2015).  When experiments were performed in the presence of the 
cyclooxygenase inhibitor, indomethacin, at a concentration known to block PGE2 
 13 
production by macrophages completely, there was no improvement in the inhibitory 
activity of salbutamol. Altogether these studies demonstrate that even when the 
experimental system is geared to potentially facilitate increased inhibitory activity, the 
extent of inhibition seen with salbutamol was still relatively modest.   
In addition to short-acting ȕ-agonists, the effects of the long-acting ȕ-agonists 
salmeterol, formoterol and indacaterol were also studied in this system.  Salmeterol 
and indacaterol were reasonably effective inhibitors of cytokine generation from lung 
macrophages whereas formoterol was ineffective.  These findings differ with those 
reported for MDM in which both formoterol and salmeterol were capable of reducing 
the extent of LPS-induced cytokine generation (Donnelly et al., 2010).  Indeed, our 
own studies indicate that all the short-acting ȕ-agonists tested (isoprenaline, 
salbutamol and terbutaline) as well as the long-acting ȕ-agonist formoterol are 
considerably more effective inhibitors of cytokine generation in MDM than in lung 
macrophages (Fig. 5).  These findings highlight some obvious functional differences 
between MDM and lung macrophages that may reflect influences related to site (lung 
cf blood), extent of macrophage differentiation or exposure to environmental factors.  
It was noteworthy that indacaterol and salmeterol showed some effectiveness 
as inhibitors of LPS-induced TNFĮ generation but were unable to prevent TNFĮ 
release induced by poly(I:C).  LPS is a bacterial product that signals through Toll-like 
receptor (TLR)4 whereas poly(I:C) is a viral mimic that acts through TLR3 (Akira et 
al., 2006).  The disparate mechanisms of action of these two stimuli could underpin 
the relative effectiveness of ȕ-agonists against TNFĮ release induced by the two 
stimuli. These data could also suggest that ȕ-agonists might provide greater anti-
inflammatory potential when macrophages are activated by bacteria rather than 
viruses. 
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It was of interest that although indacaterol and salmeterol had some effect as 
inhibitors of LPS-induced TN)ĮDQG,/-6 generation, neither agonist was effective 
against IL-8.  The reasons for this outcome are difficult to reconcile since there is a 
strong likelihood that LPS-induced cytokine release is mediated through a common 
pathway involving activation of nuclear factor-NB (Blackwell and Christman, 1997).  
One possible explanation might relate to the prodigious quantities of IL-8 generated 
by macrophages following LPS activation which seem far greater than the quantitities 
RIHLWKHU71)ĮRU,/-6 released.  These quantities of IL-8 might be difficult IRUDȕ-
adrenoceptor agonist to counter.  The reason why macrophages release a great deal of 
IL-8 may be connected to the kinetics of cytokine generation.  Whereas the generation 
RI71)ĮDQG,/-6 appear to plateau by 16 h after LPS challenge, IL-8 generation 
appears to be continuing even after 22 h (see Supplemental Information, Fig. S1).  
These findings suggest that there may be differences in the mechanism by which 
individual cytokines are generated by macrophages following LPS challenge.        
As well as considering effects on pro-inflammatory cytokine generation, we 
DOVRH[SORUHGWKHSRVVLELOLW\WKDWȕ-adrenoceptor agonists might influence the 
generation of the anti-inflammatory cytokine, IL-10.  A previous study in  murine 
PDFURSKDJHVGHPRQVWUDWHGWKDWȕ2-adrenoceptor activation led to increased generation 
of IL-10 and a switch in phenotype of macrophages from M1 (pro-inflammatory) to 
M2 (anti-inflammatory) (Grailer et al., 2014).  ȕ-adrenoceptor agonists had no such 
effect on IL-10 generation from human lung macrophages.  Indeed, macrophages 
activated with LPS were comparatively weak releasers of IL-10 compared to the pro-
LQIODPPDWRU\F\WRNLQHV71)Į,/-6 and IL-8.  These findings highlight the fact that 
human lung macrophages display a prominently pro-inflammatory phenotype which 
is in keeping with the finding of others (Tomlinson et al., 2012).   
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We performed some experiments to determine whether the inhibitory effects 
of indacaterol and salmeterol were receptor-mediated.  The ȕ2-adrenoceptor 
antagonist, ICI-118,551, antagonized the inhibitory effects of indacaterol but not 
those of salmeterol.  These findings suggest that indacaterol acts at ȕ2-adrenoceptors 
to stabilise macrophages but that salmeterol does not.   
Functional desensitization experiments were performed in order to evaluate 
further the mechanisms by which indacaterol and salmeterol act in macrophages.  A 
long-term desensitizing treatment of macrophages with indacaterol led to a loss in the 
subsequent ability of indacaterol to inhibit TNFĮ generation from macrophages.  
These findings support the idea that the effects of indacaterol are receptor-mediated.   
This same desensitizing treatment with indacaterol had no effect on the subsequent 
inhibitory effects of salmeterol suggesting that indacaterol and salmeterol act at 
different targets.  A long-term desensitizing treatment of macrophages with salmeterol 
did not desensitize the subsequent response to salmeterol.  These findings suggest that 
the inhibitory effects of salmeterol are probably not receptor-mediated.  
In summary, the present study demonstrates that while ȕ-adrenoceptor 
agonists may inhibit cytokine generation from human lung macrophages these anti-
inflammatory effects are modest. 
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Figure legends 
Fig. 1 Effects of short-acting and long-acting ȕ-agonists on cytokine generation.  
Macrophages were incubated (30 min) with or without isoprenaline (iso), terbutaline 
(ter), salbutamol (salb), formoterol (form), salmeterol (salm), indacaterol (inda) all at 
10-5 M or dexamethasone (dex; 10-7 M) before challenge with LPS (10 ng/ml).  After 
22 h, cell supernatants were harvested and the amount of (A) TNFĮ, (B) IL-6, (C) IL-
8 and (D) IL-10 generated was assessed.  Values are means ± S.E.M., n=6 (A) or n=5 
(B, C, D).  Statistically significant (P < 0.05 at least) levels of inhibition, compared to 
the unblocked control, are indicated by an asterisk. 
 
Fig. 2 Effects of ȕ-agonists on TNFĮ generation induced by poly(I:C).  Macrophages 
were incubated (30 min) with or without salbutamol (salb), salmeterol (salm), 
indacaterol (inda) all at 10-5 M or dexamethasone (dex; 10-7 M) before challenge with 
either (A) LPS (10 ng/ml) or poly(I:C) (10 µg/ml).  After 22 h, cell supernatants were 
harvested and the amount of TNFĮ generated was assessed.  Values are means ± 
S.E.M., n=4.  Statistically significant (P < 0.05 at least) levels of inhibition, compared 
to the unblocked control, are indicated by an asterisk.  
 
Fig. 3 Effects of stimulus strength on the inhibitory effects of salbutamol.  
Macrophages were incubated (30 min) with or without salbutamol (10-6 M) before 
challenge with a range of LPS concentrations (0.1, 1 or 10 ng/ml) for 22 h.  Cell 
supernatants were recovered and TNFĮ content assessed.  Values are means ± S.E.M., 
n=3.  Statistically significant (P < 0.05) levels of inhibition by salbutamol, compared 
to the corresponding unblocked control, are indicated by an asterisk. 
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Fig. 4 Effect of indomethacin on the inhibitory effects of salbutamol.  Macrophages 
were incubated (30 min) with or without indomethacin (10-6 M) and then incubated 
together with or without salbutamol before challenge with LPS (1 ng/ml).  After 22 h, 
cell supernatants were harvested and the amount of TNFĮ generated was assessed.  
Values are expressed as the % inhibition of the unblocked releases of TNFĮ which 
were 395 ± 123 ng/ml (- indomethacin) and 454 ± 233 ng/ml (+ indomethacin).  
Values are means ± S.E.M., n=4 (-indomethacin) and n=6 (+ indomethacin).   
 
Fig. 5 &RPSDULVRQRIWKHHIIHFWVRIȕ-agonists on monocyte-derived macrophages 
(MDM) and human lung macrophages (HLM).  Cells were incubated (30 min) with or 
without isoprenaline (iso), terbutaline (ter), salbutamol (salb), formoterol (form), 
salmeterol (salm), indacaterol (inda) all at 10-5 M or dexamethasone (dex; 10-7 M) 
before challenge with LPS (10 ng/ml).  After 22 h, cell supernatants were harvested 
DQGWKHDPRXQWRI71)ĮJHQHUDWHGZDVDVVHVVHG9DOXHVDUHH[SUHVVHGDVWKH
inhibition of the control unblRFNHG71)ĮJHQHUDWLRQZKLFKZDVDQG
± 271 pg/ml for MDM and HLM, respectively. Values are means ± S.E.M., n=4 
0'0RUQ +/07KHHIIHFWLYHQHVVRIDJLYHQȕ-DJRQLVWWRLQKLELW71)Į
generation between cell types was compared statistically. Significant (P < 0.05 at 
least) differences are indicated by asterisks. 
 
Fig. 6 Effects of ICI-118,551 on the inhibitory effects of formoterol and salmeterol.  
Macrophages were incubated (1 h) with (+) or without (-) ICI-118,551 (10-6 M) and 
then with or without (A) indacaterol (10-5 M) or (B) salmeterol (10-5 M) for a further 
30 min.  The cells were then challenged with LPS (10 ng/ml) for 22 h after which the 
amount of TNFĮ generated in the supernatants was assessed.  Values are means ± 
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S.E.M., n=4.  Statistically significant differences compared to control (grey bar) are 
indicated by asterisks (P < 0.05 at least).     
 
Fig. 7 Desensitization of the inhibitory effects of indacaterol but not those of 
salmeterol.  Macrophages were incubated (24 h) with (+) or without (-) a 
desensitizing treatment (1st incubation) of beta agonist (10-5 M).  After this incubation, 
the cells were washed three times.  The cells were then incubated (30 min) with (+) or 
without (-) a beta agonist (10-5 M) for a second time (2nd incubation) to determine 
inhibitory effects after the desensitizing treatment.  The cells were then challenged 
with LPS (10 ng/ml) for 22 h after which the amount of TNFĮ generated in the 
supernatants was assessed.  The figure shows (A) the effects of indacaterol pre-
treatment on the subsequent inhibition by indacaterol and (B) the effects of salmeterol 
pre-treatment on the subsequent inhibition by salmeterol.  Values are means ± S.E.M., 
n=5 (A) or n=4 (B).  Statistically significant comparisons are indicated by asterisks (P 
< 0.05 at least) and non-VLJQLILFDQWFRPSDULVRQVE\µQV¶     
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